AML - ACUTE MYELOID LEUKEMIA
Clinical trials for AML - ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new AML - ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for AML - ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for AML patients too frail for harsh chemo: milder drug combo aims to wipe out cancer cells fast
Disease control Not yet recruitingThis study tests a new treatment plan for adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. The approach uses a drug called selinexor, either alone or with very low doses of other chemo drugs, to quickly reduce cancer cel…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 26, 2026 11:26 UTC
-
Which chemo works best before a transplant? new trial aims to find out.
Disease control Not yet recruitingThis study compares two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). About 220 adults whose cancer is in remission or stable will take part. The goal is to see whic…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated May 26, 2026 11:24 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-stage trial tests a new treatment for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target a protein …
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 11:23 UTC
-
Experimental CAR-T therapy targets tough childhood leukemia
Disease control Not yet recruitingThis early-phase study tests a new treatment called CLL-1 CAR-T for children aged 3 to 18 with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack leukemia cells. …
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated May 26, 2026 11:21 UTC
-
New hope for AML patients: drug combo aims to beat standard chemo
Disease control Not yet recruitingThis study compares a new three-drug combination (gilteritinib, azacitidine, and venetoclax) to standard chemotherapy for adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 participants aged 18-75 who are healthy enough for inte…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: PHASE2, PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated May 26, 2026 11:18 UTC
-
Experimental CAR-T therapy aims to tackle tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML). Ten participants will receive a sequence of two types of CAR-T cells designed to target leukemia cells, followed by a stem cell transplant. The main goal is to check s…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 11:18 UTC
-
Engineered immune cells take on stubborn leukemia in early trial
Disease control Not yet recruitingThis study tests a new treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to better find and attack leukemia cells. The goal is to see if this therapy can safe…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated May 26, 2026 11:17 UTC
-
New immune-boosting transplant aims to stop leukemia relapse
Disease control Not yet recruitingThis study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back after transplant. About 28 part…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Antonio Pierini • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New drug combo may boost transplant success in leukemia
Disease control Not yet recruitingThis study tests whether adding the drug venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). About 27 adults aged 18–75 will receive this experimental cond…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Two-Punch therapy takes on tough leukemia
Disease control Not yet recruitingThis study tests a two-step treatment for people with a tough type of leukemia (AML) that has come back or not responded to standard chemo. First, patients receive a special immune cell therapy (CLL1 CAR-T) to target cancer cells, followed by a stem cell transplant to rebuild a h…
Matched conditions: AML - ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 20, 2026 12:08 UTC